LUDG
Ludwig Enterprises, Inc.
Price Chart
Latest Quote
$0.02
| Previous Close | $0.02 |
| Open | $0.02 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 800 |
Stock Information
| Shares Outstanding | 167.17M |
| Total Debt | $2.70M |
| Cash Equivalents | $18K |
| Net Income | $-1.48M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $3.34M |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.00M |
| Income | $-1.48M |
| Book/sh | $-0.02 |
| Cash/sh | $0.00 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.05 |
Returns & Margins
| ROA | -149.48% |
Ownership
| Insider Ownership | 0.63% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.83 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.03 |
| SMA50 | $0.03 |
| SMA200 | $0.05 |
| RSI | 22.22 |
| ATR | 0.0019 |
| Shares Float | 94.15M |
| Volatility | 1.56 |
Performance History
| Week | -9.09% |
| Month | -35.48% |
| Quarter | -50.00% |
| 6 Months | -64.91% |
| YTD | -60.78% |
| Year | -75.61% |
| 3 Years | -86.67% |
| 5 Years | -50.00% |
| 10 Years | +81.82% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.02 | 0 |
| 2026-06-23 | $0.02 | 0 |
| 2026-06-22 | $0.02 | 800 |
| 2026-06-18 | $0.02 | 11,700 |
| 2026-06-17 | $0.02 | 200 |
| 2026-06-16 | $0.02 | 0 |
| 2026-06-15 | $0.02 | 0 |
| 2026-06-12 | $0.02 | 38,600 |
| 2026-06-11 | $0.02 | 0 |
| 2026-06-10 | $0.02 | 4,000 |
| 2026-06-09 | $0.03 | 0 |
| 2026-06-08 | $0.03 | 1,000 |
| 2026-06-05 | $0.03 | 0 |
| 2026-06-04 | $0.03 | 0 |
| 2026-06-03 | $0.03 | 0 |
| 2026-06-02 | $0.03 | 0 |
| 2026-06-01 | $0.03 | 36,400 |
| 2026-05-29 | $0.04 | 54,000 |
| 2026-05-28 | $0.03 | 0 |
| 2026-05-27 | $0.03 | 23,000 |
| 2026-05-26 | $0.03 | 0 |
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. operates as a genomic technology focused on developing testing approaches for inflammation-related chronic diseases, including cancers in the United States. The company integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits for cancer identification. It offers mRNA-based screening to provide early insights of potential health risks. The company develops Revealia Breast test, a non-invasive cheek swab screening kit designed to identify and analyze molecular signatures in mRNA expression associated with inflammation-related biological processes associated with the presence of breast cancer. Ludwig Enterprises, Inc. was founded in 1988 and is based in Miami, Florida.
đ° Latest News
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $217 | $0 | $0 |
| Operating Revenue | $217 | $0 | $0 |
| Reconciled Cost Of Revenue | - | $0 | $0 |
| Cost Of Revenue | - | $0 | $0 |
| Expenses | |||
| Interest Expense | $71,794 | $485,228 | $449,120 |
| Total Expenses | $1,298,406 | $1,375,761 | $560,505 |
| Other Income Expense | $-1,004,574 | $-517,454 | $44,475 |
| Other Non Operating Income Expenses | $-1,004,574 | $-517,454 | - |
| Net Non Operating Interest Income Expense | $-748,924 | $-485,228 | $-449,120 |
| Total Other Finance Cost | $677,130 | - | - |
| Interest Expense Non Operating | $71,794 | $485,228 | $449,120 |
| Operating Expense | $1,298,406 | $1,375,761 | $560,505 |
| General And Administrative Expense | $1,132,785 | $964,747 | $447,260 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-3,051,687 | $-2,378,443 | $-965,150 |
| Net Interest Income | $-748,924 | $-485,228 | $-449,120 |
| Normalized Income | $-3,051,687 | $-2,378,443 | $-1,009,625 |
| Net Income From Continuing And Discontinued Operation | $-3,016,884 | $-2,456,550 | $-965,150 |
| Total Operating Income As Reported | $-1,298,189 | $-1,375,761 | $-560,505 |
| Net Income Common Stockholders | $-3,016,884 | $-2,456,550 | $-965,150 |
| Net Income | $-3,016,884 | $-2,456,550 | $-965,150 |
| Net Income Including Noncontrolling Interests | $-3,016,884 | $-2,456,550 | $-965,150 |
| Net Income Discontinuous Operations | $34,803 | $-78,107 | - |
| Net Income Continuous Operations | $-3,051,687 | $-2,378,443 | $-965,150 |
| Pretax Income | $-3,051,687 | $-2,378,443 | $-965,150 |
| Operating Income | $-1,298,189 | $-1,375,761 | $-560,505 |
| Special Income Charges | - | $0 | $44,475 |
| Gross Profit | - | $0 | $0 |
| Per Share | |||
| Diluted EPS | $-0.02 | $-0.01 | $-0.00 |
| Basic EPS | $-0.02 | $-0.01 | $-0.00 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,979,893 | $-1,893,215 | $-560,505 |
| EBITDA (Bullshit earnings) | $-2,979,893 | $-1,893,215 | $-516,030 |
| EBIT | $-2,979,893 | $-1,893,215 | $-516,030 |
| Diluted Average Shares | $158,606,794 | $286,563,789 | $313,736,463 |
| Basic Average Shares | $158,606,794 | $286,563,789 | $313,736,463 |
| Diluted NI Availto Com Stockholders | $-3,016,884 | $-2,456,550 | $-965,150 |
| Tax Provision | $0 | $0 | - |
| Research And Development | $165,621 | $411,014 | $113,245 |
| Selling General And Administration | $1,132,785 | $964,747 | $447,260 |
| Other Gand A | $1,132,785 | $964,747 | $447,260 |
| Total Unusual Items | - | $0 | $44,475 |
| Total Unusual Items Excluding Goodwill | - | $0 | $44,475 |
| Other Special Charges | - | - | $-44,475 |
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-2,378,145 | $-1,461,565 | $-826,167 |
| Total Assets | $197,556 | $112,468 | $516,195 |
| Total Non Current Assets | $0 | $0 | $0 |
| Current Assets | $197,556 | $112,468 | $516,195 |
| Assets Held For Sale Current | $0 | $105,205 | - |
| Current Deferred Assets | $60,000 | $0 | - |
| Prepaid Assets | $27,767 | $0 | $0 |
| Inventory | $3,048 | $0 | - |
| Receivables | $100,000 | $0 | - |
| Notes Receivable | $100,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $6,741 | $7,263 | $516,195 |
| Cash And Cash Equivalents | $6,741 | $7,263 | $516,195 |
| Cash Financial | $6,741 | $7,263 | $516,195 |
| Debt | |||
| Net Debt | $1,941,976 | $1,362,746 | $819,285 |
| Total Debt | $1,948,717 | $1,370,009 | $1,335,480 |
| Current Debt And Capital Lease Obligation | $1,948,717 | $1,370,009 | $1,335,480 |
| Current Debt | $1,948,717 | $1,370,009 | $1,335,480 |
| Other Current Borrowings | $578,708 | $100,000 | $828,344 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $2,575,701 | $1,574,033 | $1,342,362 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 |
| Current Liabilities | $2,575,701 | $1,574,033 | $1,342,362 |
| Current Notes Payable | $1,370,009 | $1,370,009 | $507,136 |
| Payables And Accrued Expenses | $626,984 | $204,024 | $6,882 |
| Payables | $626,984 | $204,024 | - |
| Accounts Payable | $621,984 | $204,024 | - |
| Equity | |||
| Common Stock Equity | $-2,385,145 | $-1,468,565 | $-833,167 |
| Preferred Stock Equity | $7,000 | $7,000 | $7,000 |
| Total Equity Gross Minority Interest | $-2,378,145 | $-1,461,565 | $-826,167 |
| Stockholders Equity | $-2,378,145 | $-1,461,565 | $-826,167 |
| Retained Earnings | $-7,259,366 | $-4,242,482 | $-1,785,932 |
| Other | |||
| Ordinary Shares Number | $160,512,807 | $155,464,808 | $315,188,929 |
| Share Issued | $160,512,807 | $155,464,808 | $315,188,929 |
| Tangible Book Value | $-2,385,145 | $-1,468,565 | $-833,167 |
| Invested Capital | $-436,428 | $-98,556 | $502,313 |
| Working Capital | $-2,378,145 | $-1,461,565 | $-826,167 |
| Total Capitalization | $-2,378,145 | $-1,461,565 | $-826,167 |
| Additional Paid In Capital | $4,713,710 | $2,618,454 | $637,577 |
| Capital Stock | $167,511 | $162,463 | $322,188 |
| Common Stock | $160,511 | $155,463 | $315,188 |
| Preferred Stock | $7,000 | $7,000 | $7,000 |
| Dueto Related Parties Current | $5,000 | $0 | - |
| Treasury Shares Number | - | $0 | $0 |
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-660,302 | $-647,860 | $-444,805 |
| Operating Activities | |||
| Operating Cash Flow | $-660,302 | $-647,860 | $-444,805 |
| Cash Flow From Continuing Operating Activities | $-660,302 | $-647,860 | $-444,805 |
| Operating Gains Losses | $-203,319 | - | $-44,475 |
| Financing Activities | |||
| Financing Cash Flow | $558,708 | $240,000 | $836,000 |
| Cash Flow From Continuing Financing Activities | $558,708 | $240,000 | $836,000 |
| Net Other Financing Charges | $-5,000 | - | - |
| Issuance Of Capital Stock | - | $0 | $6,000 |
| Net Preferred Stock Issuance | - | $0 | $6,000 |
| Preferred Stock Issuance | - | $0 | $6,000 |
| Other | |||
| Repayment Of Debt | $-55,000 | $0 | - |
| Issuance Of Debt | $618,708 | $240,000 | $830,000 |
| Interest Paid Supplemental Data | $5,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $6,741 | $108,335 | $516,195 |
| Beginning Cash Position | $108,335 | $516,195 | $125,000 |
| Changes In Cash | $-101,594 | $-407,860 | $391,195 |
| Net Issuance Payments Of Debt | $563,708 | $240,000 | $830,000 |
| Net Short Term Debt Issuance | $563,708 | $240,000 | $830,000 |
| Short Term Debt Payments | $-55,000 | $0 | - |
| Short Term Debt Issuance | $618,708 | $240,000 | $830,000 |
| Change In Working Capital | $444,597 | $193,009 | $14,068 |
| Change In Other Working Capital | $-50,000 | - | - |
| Change In Payables And Accrued Expense | $521,279 | $197,142 | $14,068 |
| Change In Prepaid Assets | $-23,634 | $-4,133 | $0 |
| Change In Inventory | $-3,048 | $0 | - |
| Other Non Cash Items | $2,115,304 | $1,615,681 | $550,752 |
| Gain Loss On Sale Of Business | $-203,319 | $0 | - |
| Net Income From Continuing Operations | $-3,016,884 | $-2,456,550 | $-965,150 |